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Abstract
In eutherian mammals, embryonic growth and survival is dependent on the formation of the placenta, an organ that
facilitates the efficient exchange of oxygen, nutrients, and metabolic waste between the maternal and fetal blood supplies.
Key to the placenta’s function is the formation of its vascular labyrinth, a series of finely branched vessels whose molecular
ontogeny remains largely undefined. In this report, we demonstrate that HOXA13 plays an essential role in labyrinth vessel
formation. In the absence of HOXA13 function, placental endothelial cell morphology is altered, causing a loss in vessel wall
integrity, edema of the embryonic blood vessels, and mid-gestational lethality. Microarray analysis of wild-type and mutant
placentas revealed significant changes in endothelial gene expression profiles. Notably, pro-vascular genes, including Tie2
and Foxf1, exhibited reduced expression in the mutant endothelia, which also exhibited elevated expression of genes
normally expressed in lymphatic or sinusoidal endothelia. ChIP analysis of HOXA13–DNA complexes in the placenta
confirmed that HOXA13 binds the Tie2 and Foxf1 promoters in vivo. In vitro, HOXA13 binds sequences present in the Tie2
and Foxf1 promoters with high affinity (Kd=27–42 nM) and HOXA13 can use these bound promoter regions to direct gene
expression. Taken together, these findings demonstrate that HOXA13 directly regulates Tie2 and Foxf1 in the placental
labyrinth endothelia, providing a functional explanation for the mid-gestational lethality exhibited by Hoxa13 mutant
embryos as well as a novel transcriptional program necessary for the specification of the labyrinth vascular endothelia.
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Introduction
For placental mammals, fetal development is contained in an
intrauterine environment where the efficient exchange of oxygen,
nutrients, and metabolic waste between the maternal and fetal
blood supplies is facilitated by the placenta. Central to the
placenta’s function is its vascular labyrinth, a juxtaposed series of
finely-branched blood vessels and trophoblasts that regulate
nutrient and waste exchange while maintaining the separation of
the maternal and fetal blood supplies [1]. After implantation,
labyrinth vascularization proceeds from the allantois, where
angiogenic and vasculogenic processes promote the formation of
a dense, highly arborized vascular bed [2–7]. The formation of the
labyrinth vascular bed requires many of the same signals
controlling embryonic vascular development including: VEGF
and its associated receptors FLT1, FLK1, and NEUROPILIN-1,
as well as ANG-1 and ANG-2 and its receptor TIE-2 [8–16].
Interestingly, while loss of function studies clearly demonstrate that
transcription factors such as: TBX4, CDX2, CDX4, HAND1,
DLX3, FOXF1, and CITED2 are required for placental
development, the target genes regulated by these proteins in the
developing placenta are largely undefined [3,17–26]. In this
report, we describe a novel role for HOXA13 in the developing
placenta and identify both direct and indirect targets of HOXA13
functioning in the placental labyrinth endothelia. In the absence of
HOXA13 function, labyrinth endothelial cell morphology, vessel
branching, and vessel integrity are compromised, a consequence
we attribute to a loss in the regulation of several essential pro-
vascular genes. Chromatin immunoprecipitation of the HOXA13-
DNA complexes confirmed that HOXA13 directly associates with
the Tie2 and Foxf1 promoters in vivo in the developing placenta.
Quantitation of HOXA13’s affinity for these promoter regions
confirmed that HOXA13 binds these regions with high affinity
and can utilize these bound DNA sequences to facilitate gene
expression in vitro. Together these findings reveal a novel
temporal and spatial domain for HOXA13 function in the
developing embryo and identify a key transcriptional hierarchy
necessary for the development of the placental vascular labyrinth.
Results
Hoxa13 Is Expressed Throughout Placental Labyrinth
Development
Among the 39 murine Hox genes, only mutations in Hoxa13
cause mid-gestational lethality from embryonic day (E) 11–15.5
[27–29]. Initially, this phenotype was attributed to premature
stenosis of the umbilical arteries [29]. Extensive analysis of the
umbilical artery (UA) defect in Hoxa13 homozygous mutants
revealed that only one of the two UAs exhibited complete stenosis
from E11.5–15.5 (Figure 1A and 1B). This finding prompted the
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mid-gestational lethality. Because malformations of the heart and
placenta are the most commonly cited reasons for mid-gestational
lethality, we first examined whether Hoxa13 is expressed in the
developing heart or placenta [30–34]. No HOXA13 expression
was detected in the cardiac crescent; however, the earliest
component of the placenta, the allantoic bud mesoderm, strongly
expressed HOXA13 from E7.75 and maintained expression in the
maturing allantois and developing labyrinth microvessels at E8.5
and E9.5 respectively (Figures 1C–1G and 2). At E10.5, HOXA13
expression was readily detected in the developing placental
labyrinth (Figures 1H and 2) whereas the chorionic ectoderm
exhibited little or no HOXA13 expression from E9.5 to E10.5
(Figures 1E–1H, 2). To note, the timing and occurrence of
chorioallantoic fusion was unaffected by the loss of HOXA13
function (data not shown).
HOXA13 Functions in the Labyrinth Vascular Endothelia
To determine the identity of the cells expressing HOXA13 in
developing labyrinth, we examined whether these cells co-express
the endothelial marker PECAM-1 (Figure 3) [35–37]. Character-
ization of HOXA13 and PECAM-1 expression confirmed that
only the cells expressing PECAM-1 (cell surface) also express
HOXA13 (nucleus), suggesting that HOXA13 is functioning in the
labyrinth vascular endothelial cells (EC) (Figure 3A–3F). HOXA13
expression was not detected in the placental trophoblasts (data not
shown). Interestingly, the elongated morphology normally attri-
buted to the labyrinth vascular endothelia was also affected in
homozygous mutants, which appeared rounded compared to
controls in the E12.5 labyrinths (Figure 3C and 3D). To determine
the onset of the EC phenotype, we characterized the labyrinth
vessels at E10.5 (Figure 3E and 3F). At E10.5, the EC in both the
heterozygous control and homozygous mutant labyrinths exhib-
ited only the rounded EC morphology (Figure 3E and 3F). This
result suggests that the vascular specification of the EC, as
indicated by their elongated morphology, occurs between E10.5
and E12.5 and denotes when the loss of HOXA13 function
phenotype first manifests in the developing labyrinth EC
(Figure 3C–3F). Close examination of the affected EC using
transmission electron microscopy confirmed the timing of the
onset of this phenotype as wild type EC exhibited lengthening of
the cell body as early at E11.5 whereas homozygous mutant EC
exhibited shortened cell bodies that lacked uniform contact with
the underlying vessel walls (Figure 4A–4D). Finally, consistent with
the reduction in the EC cell body was the loss of vessel wall
integrity in the E11.5 and E13.5 mutant vessels, resulting in
extracellular edema between mutant labyrinth vessels and the
underlying syncytiotrophoblasts, while edema was not detected in
the wild type labyrinths (Figure 4A–4D).
No gross morphological defects were observed in the basement
membranes between the EC and the syncytiotrophoblast
(Figure 4E and 4F). Quantitation of the affected labyrinth EC in
the homozygous mutants revealed that nearly 50 percent exhibited
an intermediate or grossly affected morphology compared to only
12 percent for age-matched controls (Figure 4G). Finally, the
affected EC did not appear apoptotic as the nuclei lacked a
pyknotic phenotype as well as TUNEL positive staining (Figure 4
and unpublished data).
Labyrinth Vascular Branching and Size Are Reduced in
Hoxa13 Homozygous Mutants
As the umbilical vessels cross the chorionic plate, they exhibit
non-sprouting angiogenesis parallel to the chorionic plate to
produce the chorionic plate vessels, followed by additional EC
migration and branching angiogenesis into the labyrinth to create
a complex vascular tree (see Figure 2). In the murine placental
labyrinth, these vascular branches are interconnected, signifying
that intussusceptive angiogenesis and vessel fusion also play a role
in their angiogenic remodeling [38,39]. Recognizing that EC
mediate many of the angiogenic processes necessary for vessel
remodeling and branching, we hypothesized that defects in the
mutant labyrinth EC would affect vessel branching, which would
compromise the capacity of this structure to sustain embryonic
survival (Figures 2–4) [40–47]. To best visualize the branched
vasculature within the labyrinth, we utilized whole tissue
immunohistochemistry using the PECAM-1 antibody and hemi-
sected placentas.
Indeed, while the initial vascular invasion of the chorionic plate
at E10.5 appears normal in Hoxa13 homozygous mutants, there is
a qualitative reduction in the level of PECAM-1 staining of the
labyrinth vasculature as early as E11.5 (Figure S1). Quantitation of
the vascular branches in the mutant and control placental
labyrinths at E13.5 confirmed that the number of branches is
reduced in the Hoxa13 homozygous mutants which exhibited 33
(66.3) branches per 400 mm
2 grid analyzed, whereas wild type
and heterozygous mutant controls contained 56 (612.7) and 55
(69.7) vessel branches respectively (Figure 5). Qualitatively, the
reduction in labyrinth vascularity in homozygous mutants was
persistent throughout labyrinth development which is complete by
E14.5, suggesting that decreased vessel branching is phenotypic of
the loss of HOXA13 function rather than a delay in the labyrinth
maturation (Figures 3, 5, and S1) [48]. Next, because changes in
vessel branching can also affect the overall size of the labyrinth, we
examined whether the labyrinth region was smaller in Hoxa13
mutant placentas. Analysis of labyrinth sections taken from E13.5
wild type and Hoxa13 homozygous mutants confirmed that the
mutant labyrinths were nearly half the thickness as their age-
matched controls (8006200 mm vs. 16006250 mm) (Figure 6).
Since defects in endothelial cell migration can also contribute to
perturbations in vessel branching, we examined whether Hoxa13
Author Summary
Defects in placental development are a common cause of
mid-gestational lethality. Key to the placenta’s function is
its vascular labyrinth, a series of finely branched vessels
that facilitate the efficient exchange of gases, nutrients,
and metabolic waste between the maternal and fetal
blood supplies. In this study, we identify a novel role for
the transcription factor HOXA13 in formation of the
placental vascular labyrinth. In the absence of HOXA13
function, labyrinth vessel branching and endothelial
specification is compromised, causing mid-gestational
lethality due to placental insufficiency. Analysis of the
genes affected by the loss of HOXA13 function revealed
significant reductions in the expression of several pro-
vascular genes, including Tie2 and Foxf1. Analysis of the
Tie2 and Foxf1 promoters confirmed that HOXA13 binds
sites present in each promoter with high affinity in the
placenta, and in vitro, HOXA13 can use these bound
sequences to regulate gene expression. These results
suggest that Tie2 and Foxf1 are direct transcriptional
targets of HOXA13 in the developing placental labyrinth,
providing a novel transcriptional pathway to consider
when examining pathologies of the placenta and placental
insufficiency, as well as the evolutionary mechanisms
required for the emergence of the vascular placenta in
eutherian mammals.
HOXA13 Function in the Placenta
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novo angiogenesis (Figure 7). A comparison of mutant and
heterozygous control cultured arterial sections revealed compara-
ble levels of neo-vessel production after five days of growth
(Figure 7A and 7B and 7D and 7E). Characterization of the cells
contributing to the neo-vessels revealed strong HOXA13 expres-
sion in the PECAM-1 positive endothelia in both heterozygous
and homozygous mutant (Figure 7C and 7F). This result suggests
that endothelial cell migration is not affected by the loss of
HOXA13 function in the in vitro angiogenesis assay.
Taken together, these results suggest that placental insufficiency
caused by decreased labyrinth vascularity and size may be causing
the mid-gestational lethality associated with the loss of HOXA13
function. To test this hypothesis we examined the developing
heart, an organ that does not express Hoxa13 but is severely
affected by placental insufficiency [28,29,49–53]. Analysis of
E14.5 hearts from heterozygous control and homozygous mutants
revealed a substantial thinning of the right and left ventricular
walls in homozygous mutants (Figure 8). Quantitation of the left
ventricular wall thicknesses confirmed nearly a 43% reduction in
wall thicknesses in homozygous mutants which contained an
average of 3.6 (61.1) cells per wall section measurement versus 6.3
(60.8) cells in the comparable sections of age-matched heterozy-
gous controls (Figure 8C and 4D).
The Loss of HOXA13 Function Causes Mis-Expression of
Pro-Vascular and Non-Capillary Endothelial Genes
To identify candidate HOXA13 target genes which are
functioning in the placental labyrinth, we performed microarray
analysis on E13.5 labyrinth tissues. Twelve microarray hybridiza-
tions (6 mutant; 6 wild type) were performed using independent
isolates of placental labyrinth total RNA. Statistical analysis of the
Figure 1. Early expression of Hoxa13 in the allantois and its derivatives. (A, B) HOXA13 is expressed in the umbilical arteries which partially
stenose (white arrow) in Hoxa13 homozygous mutants. (C) Fluorescent and bright field image of an E7.75 embryo expressing HOXA13-GFP.
AL=allantois, CC=cardiac crescent. (D) HOXA13-GFP is expressed throughout the allantois at E8.5. Red signal=detection of the HOXA13-GFP fusion
protein using a GFP antibody (denoted as a-GFP). Green signal indicates detection of the endogenous HOXA13-GFP fusion protein. Yellow signal
(Merged) indicates the co-localization of the detected HOXA13-GFP protein and the a-GFP immuno-positive cells, confirming the detected green
fluorescence to be derived from the mutant HOXA13-GFP fusion protein throughout the allantois. AL=allantois; EM=embryo proper. (E, F)
Cryosection of an E9.5 placenta. Green signal indicates detection of the HOXA13-GFP fusion protein in the developing labyrinth region; red signal
indicates detection of the HOXA13-GFP fusion protein using a GFP antibody (denoted as a-GFP). Note the absence of HOXA13-GFP expression in the
chorionic ectoderm (CE). Arrows denote sites of microvessel genesis. Dashed line represents chorionic plate. AS=allantoic stalk. (G) Sagittal section of
an E9.5 embryo and developing placenta. Note that HOXA13-GFP expression is maintained in the allantoic stalk as it contributes to the developing
allantoic vessels (arrows) as well as the developing chorionic plate vessels (asterisks). Dashed line denotes the developing chorionic plate.
CE=chorionic ectoderm, EM=embryo proper, AS=allantoic stalk. (H) At E10.5, HOXA13 expression is maintained in the developing labyrinth (LAB),
whereas little or no expression is detected in the chorionic ectoderm (CE). Bars are 25 mm.
doi:10.1371/journal.pgen.1000073.g001
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identified significant reductions in pro-vascular gene expression
(FDR#0.05) including: CD36, necdin, Enpp2, Adrb1, Tie2, Foxf1,
Neuropilin-1, Magel-2, and Caveolin-1 (Table 1). Interestingly, the
homozygous mutant placentas also exhibited significant over-
expression of several genes normally expressed in sinusoidal and
lymphatic endothelia including: Lyve-1, Igfbp3, Selenbp1, Bmp1, and
Ednrb (Table 2) [54–58]. Finally, genes expressed in specific
trophoblast lineages such as: gcm1 (chorionic trophoblast), esx1
(labyrinth trophoblasts), tpbp (spongiotrophoblast), Id1 (chorionic
trophoblast), and Id2 (chorionic trophoblast) exhibited no
significant changes in expression between control and Hoxa13
mutant placentas (FDR#0.05) (Figure 6 and Table 3) [59–63].
Next, to validate that the genes detected by the microarray
analysis were mis-expressed in the affected EC, we performed
quantitative real-time PCR (qRT-PCR) using total RNA derived
Figure 2. Sites of HOXA13 expression during placental labyrinth development. (A) HOXA13 is expressed in the endothelial progenitors in
the E8.0 allantois. (B) HOXA13 expression is maintained in the endothelial progenitors during chorioallantoic fusion at E8.5. (C) Between E8.75 and
E9.5, the HOXA13-expressing endothelial progenitors contribute to the developing feto-placental vessels, which mature to form the umbilical artery
(UA), chorionic plate vessels, and the vessels contributing to the placental labyrinth (D). HOXA13 is not expressed in the developing umbilical vein
(UV).
doi:10.1371/journal.pgen.1000073.g002
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expression trend determined by the microarray analysis (increased
or decreased in mutant placentas) was conserved (Table 1).
Moreover, the enrichment of the EC also caused an increase in the
detected fold-change differences between wild type and homozy-
gous mutant EC, a finding consistent with an endothelial-specific
expression pattern or function for the affected genes. Immunohis-
tochemical analysis of TIE2, LYVE-1, NEUROPILIN-1, and
ENPP2 confirmed the altered EC-specific expression levels
detected by microarray and qRTPCR (Figures 9 and S1,
Table 1, and unpublished data). In particular, the pro-vascular
receptor tyrosine kinase, TIE2, was noticeably reduced in the
mutant labyrinth EC which also express HOXA13 at E10.5–13.5
(Figures 9A–9D and S1).
HOXA13 Directly Regulates Tie2 and Foxf1
Because Tie2 and Foxf1 are strongly expressed in the placental
labyrinth and mice lacking TIE2 or FOXF1 exhibit vascular
defects most similar to those present in Hoxa13 mutant labyrinths,
we hypothesized that HOXA13 directly regulates Tie2 or Foxf1 to
facilitate labyrinth vascular development [8,39,64–70]. Testing
this hypothesis, we first examined whether HOXA13 binds the
promoters for Tie2 or Foxf1 in vivo using a HOXA13 antibody to
immunoprecipitate HOXA13-DNA complexes present in laby-
Figure 3. HOXA13 is expressed in the placental labyrinth vascular endothelia. (A, B) Analysis of HOXA13 expression (green) in
heterozygous control and homozygous mutant placentas at E12.5 reveals extensive expression throughout the vascular labyrinth. (C) HOXA13 is co-
expressed with PECAM-1 in the labyrinth endothelia, which exhibit an elongated morphology in heterozygous controls (arrowheads). (D) E12.5
homozygous mutant labyrinth endothelia also express HOXA13 (green signal) and PECAM-1 (red signal), but maintain a rounded morphology
(arrowheads). (E, F) Analysis of labyrinth vessels at E10.5 reveals co-localization of HOXA13 (green signal) and PECAM-1 (red signal) to the
undifferentiated endothelia (arrowheads), which do not exhibit an elongated vascular morphology. Bar is 10 mm for (C–F).
doi:10.1371/journal.pgen.1000073.g003
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HOXA13 antibody confirmed that it can bind both wild type and
mutant HOXA13 proteins and facilitate chromatin immunopre-
cipitation (ChIP) of HOXA13-bound gene regulatory elements
[71–73]. PCR analysis of the first 3000 base-pairs (bp) (23000 to
+1) of the Tie2 and Foxf1 promoters revealed a single region in
each locus bound by HOXA13 in wild type (not shown) and
heterozygous mutant placental labyrinths (Figure 10A and 10B).
In contrast, the homozygous mutant HOXA13 protein, which
lacks its DNA binding domain, failed to associate with the same
promoter regions (Figure 10A). Parallel ChIP assays did not detect
HOXA13 association with the promoters of other pro-vascular
genes mis-expressed in the mutant labyrinth including CD36,
Caveolin-1, and Neuropilin-1 (data not shown).
Sequence analysis of the immunoprecipitated Tie2 and Foxf1
promoter regions confirmed the presence of several of the recently
identified HOXA13 binding sites (Figure 10B) [71]. Next, using an
electrophoretic mobility shift assay (EMSA), the HOXA13 DNA
binding domain was confirmed to bind the promoter regions
detected by the ChIP assay in a concentration-dependent manner
(Figure 10C). Quantitation of HOXA13’s affinity for the Tie2 and
Foxf1 ChIP-positive regions using fluorescence polarization
anisotropy revealed high affinity for the binding sites present in
Tie2 (Kd=2761.4 nM and 22 nM61.6 nM) and Foxf1
(Kd=4864 nM) compared to a control sequence lacking the
HOXA13 binding site (Kd=250622 nM) (Figure 10D and 10E).
Next, the capacity of HOXA13 to regulate gene expression
through the 140 base-pair Tie2 and 121 base-pair Foxf1 ChIP-
positive DNA fragments was examined (Figure 10F). The pGL3-
Basic vector was selected for this analysis based on previous studies
that confirm its capacity to assess promoter/enhancer activity in
vitro, including previous characterizations of HOXA13’s capacity
to regulate transcription from minimal promoter elements [72,74–
78]. In the absence of the Tie2 or Foxf1 DNA elements, the empty
pGL3-basic luciferase plasmid exhibited only a minor increase in
luciferase expression when co-transfected with a Hoxa13 expres-
sion plasmid (Figure 10F). Similarly, the same luciferase vector
containing either the Tie2 or the Foxf1 ChIP-positive regions also
exhibited minimal luciferase expression in the absence of
HOXA13 (Figure 10F). Co-transfection with a Hoxa13 expression
vector stimulated luciferase expression from these minimal pro-
moter elements resulting in low but significant increases in
normalized luciferase expression: 3.7 fold for Tie2 and 3.2 fold
for Foxf1 (Figure 10F).
Discussion
HOXA13 Function Is Co-Opted in Labyrinth Vascular
Endothelia
While the timing of Hoxa13 expression at E7.75 was surprising
for a 59 Hox gene, its localization to the allantoic bud is consistent
with the later functions of HOXA13 in the gut, where the
contributing posterior allantoic bud mesoderm receives patterning
instructions from the 59 HOX proteins [5,28,29,79–83]. The
vascular-specific expression of Hoxa13 appears to be restricted to
the placental labyrinth, genital tubercle, and umbilical arteries;
structures whose ontogeny can be linked to tissues within the
posterior embryo [28,29,73,84]. Here, the mesenchymal functions
of HOXA13 during genitourinary development appear co-opted
to facilitate vascular specification of the labyrinth endothelia
[28,29,73,80,84]. HOXC13 also exhibits co-opted function in the
hair follicle, suggesting that the development of specialized
structures may utilize the co-opted functions of the group 13
HOX proteins [85]. While other Hox proteins such as HOXD3,
HOXB3, HOXA5, and HOXD10 have been shown to regulate
angiogenesis, our analysis of HOXA13’s function in the vascular
endothelia represents, to our knowledge, the only group 13 HOX
protein functioning in this capacity [86–89].
In the absence of HOXA13 function, labyrinth endothelial cell
integrity and vessel branching are compromised, resulting in a
Figure 4. Endothelial cell morphology is affected in the
placental labyrinth of Hoxa13 homozygous mutants. (A, B)
Transmission electron microscopy (TEM) reveals the initial elongation of
the wild-type EC in the developing labyrinth vessels, whereas
homozygous mutant littermates (B) exhibit rounded endothelia with
attenuated cell bodies. Asterisks denote the endothelial cells; arrows
depict the EC bodies in wild-type and mutant vessels. (C, D) Wild-type
controls exhibit a mature elongated endothelial cell morphology by
E13.5 (arrows), whereas homozygous mutant littermates (D) exhibit a
severe loss in the elongated morphology (arrows), causing edema in
the surrounding placental tissues (arrowheads). F=fetal vessel lumen;
M=maternal space. (E, F) No differences in basement membrane
(arrows) ultrastructure were detected in the labyrinth vessels between
wild-type and homozygous mutant embryos, confirming that the loss
of HOXA13 function is directly affecting endothelial morphology and
function. F=fetal vessel lumen; N=endothelial cell nucleus. (G)
Quantitative analysis of multiple labyrinth vessel TEM micrographs
revealed that nearly 50% of the homozygous mutant endothelia
exhibited an intermediate or severely abnormal morphology compared
to wild-type or heterozygous mutant controls.
doi:10.1371/journal.pgen.1000073.g004
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mid-gestation [27–29]. Placental insufficiency also causes second-
ary cardiac defects [49–53]. The absence of Hoxa13 expression in
the early cardiac field as well as its absence in the affected heart
tissues supports the conclusion that thinning of the ventricular
walls in Hoxa13 mutants is a secondary defect caused by placental
insufficiency.
Are HOXA13-Deficient Endothelia Assuming a Different
Cell Fate?
The over-expression of non-capillary endothelial genes in
Hoxa13 homozygous mutant labyrinths raises an intriguing
possibility that the vascular endothelia are trans-differentiating
towards a sinusoidal or lymphatic phenotype. Indeed, the genes
exhibiting the highest degree of over-expression in Hoxa13 mutant
placentas are either elevated during lymphatic re-specification or
have discrete functions in sinusoidal and/or lymphatic endothelia
including: Lyve-1, Igfbp3, Selenbp1, and Ednrb (Table 2) [54,56–
58,90–92]. Moreover, the rounded phenotype of Hoxa13 mutant
EC is also more similar to sinusoidal EC, although our analysis of
the mutant endothelia by TEM did not reveal substantial
fenestrations usually present in sinusoidal endothelia [54].
Perturbations in the expression of the transcription factor,
PROX1, also promote Lyve-1 over-expression in vascular endo-
thelia, suggesting some degree of plasticity in endothelial
specification [91,92]. Transformations of sinusoidal endothelia
towards a capillary phenotype have also been induced by
selenium, thus the over-expression of the selenium binding protein
in the mutant endothelia (Selenbp1), could alter endothelial
specification by limiting selenium bioavailability[54].
Alternatively, it is possible that the over-expression of LYVE1 in
Hoxa13 homozygous mutant EC could affect the uptake and
degradation of matrix hyaluronan, impacting endothelial cell
adhesion [90,93–97]. While mice lacking LYVE1 do not exhibit
defects in the placental labyrinth, its over-expression in Hoxa13
mutant EC may influence how these cells interact with the
underlying basement membrane resulting in the rounded appear-
ance and perturbations in EC migration [92]. Arguing against this
possibility is the result that Hoxa13 homozygous mutant EC are
competent to migrate during angiogenesis, suggesting that LYVE1
over-expression in the mutant EC is a consequence of the loss of
endothelial specification. Finally, the over-expression of the
metalloprotease, Bmp1, could also contribute to the loss in labyrinth
vascularization as BMP1 cleaves placental PROLACTIN to
produce a potent angiogenic inhibitor [55].
Loss of HOXA13 Function Does Not Affect Trophoblast
Development
Previous studies of labyrinth development suggest that signals
from the trophoblast lineages participate in labyrinth formation
and vascularization [5,13,22,50,51,53,62,63,98–102]. The normal
expression of trophoblast genes such as Gcm1, Id1, Id2 (chorionic);
Tpbp (spongiotrophoblast); and Esx1 (labyrinth trophoblast) in
Hoxa13 mutant placentas suggests that trophoblast tissues are not
affected by the loss of HOXA13 function. Instead, HOXA13
appears to be functioning in the vascular endothelia where it
regulates pro-vascular genes necessary for labyrinth vascular
development. Similar labyrinth defects are also seen in mice
lacking WNT2 and HGF which appear to be predominantly
expressed in the allantoic mesoderm and its derivatives [103,104].
Figure 5. Labyrinth vessel branching is reduced in Hoxa13 homozygous mutants. (A–D) PECAM-1 immunostaining of E13.5 hemisected
placentas revealed extensive branching of the primary labyrinth vessel in wild-type and heterozygous mutants, whereas homozygous mutant
littermates exhibited poor branching of the primary labyrinth vessels (E, F). (G) Quantitation of the labyrinth vascular branches confirmed that the
homozygous mutants labyrinths contained an average of 33 branches per 400 mm
2 grid, whereas wild-type and heterozygous mutant controls
contained an average of 56 and 55 branches, respectively, in the same unit area. Bars represent the standard deviation of six independent
assessments.
doi:10.1371/journal.pgen.1000073.g005
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suggests that tetraploid chimeras consisting of a wild type
tetraploid embryo and Hoxa13 homozygous mutant embryonic
stem cells would not be effective in rescuing the labyrinth defects
[1,105].
HOXA13 Coordinates Pro-Vascular Gene Expression To
Facilitate Labyrinth Formation
In Drosophila, HOX proteins such as UBX regulate the
formation of specific structures by controlling genes at multiple
levels of a developmental cascade [106–108]. Our analysis of
HOXA13 function during limb, genitourinary, and placental
development suggests a similar mode of gene regulation where the
combinatorial functions of direct and indirect target genes are
coordinated to facilitate the formation of specific tissues and
structures [28,71–73,80]. Evidence for this coordination is seen in
the labyrinth endothelia where genes necessary for cell adhesion
and vascular branching are concomitantly affected by the loss of
HOXA13 function including: Neuropilin-1, Enpp2, Lyve1, Caveolin-1,
Foxf1, and Tie2, resulting in hypomorphic levels of the provascular
factors necessary for labyrinth vascular development.
The binding of HOXA13 to the Tie2 and Foxf1 gene regulatory
elements in vivo and the reduction of Tie2 and Foxf1 expression in
Hoxa13 mutant labyrinths suggest that these pro-vascular genes are
direct targets of HOXA13 in the labyrinth endothelia. Indeed, the
loss of function phenotypes associated with Tie2 and Foxf1 are
consistent with the endothelial defects in Hoxa13 mutant
labyrinths. Mice lacking TIE2 exhibit lethality by E10.5 due to
Figure 6. The vascular labyrinth region is thinner in Hoxa13 homozygous mutant placentas. (A), (C) Measurements of the E12.5 labyrinth,
which is defined as the region underlying the spongiotrophoblast marker, Tpbp, revealed an average labyrinth thickness of nearly 1,600 mmi n
Hoxa13 control embryos. (B, C) Parallel analyses of age-matched Hoxa13 homozygous mutants confirmed that the labyrinth thickness is reduced to an
average thickness of 800 mm. Arrows represent the sites measured on each labyrinth section from the spongiotrophoblast to the chorionic plate to
determine labyrinth thickness using the NIH Image J software. Error bars represent the standard deviation of 16 different labyrinth sections measured
at 5 independent points for each sample.
doi:10.1371/journal.pgen.1000073.g006
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primary vascular network [39,70,109].
Foxf1 is also essential for placental development [21,110]. Mice
lacking Foxf1 exhibit mid-gestational lethality resulting from
defects in the patterning and vascularization of extra-embryonic
tissues [20]. Interestingly, Foxf1 haploinsufficiency also affects
vascular integrity, causing hemorrhaging in the lung and foregut,
suggesting that reduced Foxf1 in the Hoxa13 mutant labyrinth may
Figure 7. Analysis of endothelial cell migration and neovascularization in cultured placental primary arteries. (A, B), (D, E) Arterial
sections from heterozygous control and homozygous mutants exhibit robust neovascularization and microvessel formation in vitro. Black boxes
denote the sites examined by confocal microscopy to visualize migrating endothelia participating in microvessel formation. (C), (F) The loss of
HOXA13 function does not affect the migration and contribution of HOXA13-expressing endothelia (green nuclei) to the developing microvessels.
Note that the migrating endothelia co-express PECAM-1 (red signal). Bar is 25 mm.
doi:10.1371/journal.pgen.1000073.g007
Figure 8. Analysis of ventricular wall thickness in Hoxa13 mutants. (A, B) Analysis of hematoxylin and eosin–stained sections (7 mm) from
heterozygous control and homozygous mutant hearts at E14.5 embryos reveal qualitatively thicker ventricular walls in the heterozygous control
embryos. RV=right ventricle; LV=left ventricle. Boxes represent the enlarged regions shown in (C) and (D). (C, D) Quantitative analysis of the left
ventricular wall thicknesses revealed homozygous mutants possess an average of 3.6 (61.1) cells per linear assessment versus 6.3 (60.8) cells in
heterozygous controls, confirming that the E14.5 Hoxa13 homozygous mutants possess a thinner left ventricular wall compared to age-matched
heterozygous controls. White arrows depict the sites assessed for ventricular wall thickness using the hematoxylin-stained nuclei to determine cell
number. The measurements were taken from the trabecular wall (T) to the outer ventricular wall (VW) for each assessment.
doi:10.1371/journal.pgen.1000073.g008
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Similarly, mice lacking ENPP2 also exhibit defects in allantois,
yolk sac, and embryonic vessel formation, suggesting that this
previously identified HOXA13 target gene may function to
mediate labyrinth vascularization.
Role of HOXA13 Indirect Target Genes
Because the Neuropilin-1, Caveolin-1, and CD36 promoter regions
were not detected by the HOXA13 ChIP assay, we are presently
classifying these genes as indirect targets of HOXA13. Develop-
mentally, perturbations in Neuropilin-1, Caveolin-1, and CD36
expression are also consistent with the Hoxa13 mutant labyrinth
defects. NEUROPILIN-1, a receptor for VEGF, PlGF-2, and
VEGF-B, is essential for endothelial migration and proliferation,
and mice lacking this protein die at mid-gestation from vascular
and heart defects [14,15,111–113]. The caveolae-associated
molecules CD36 and CAVEOLIN-1 also modulate cell mobility
and permeability, angiogenesis, and intracellular trafficking, and
caveolin-1 knockout mice exhibit decreased vascular tone and
decreased angiogenic responses to exogenous stimuli [114–117].
Labyrinth Formation Requires Non-Sprouting and
Sprouting Angiogenesis
Factors regulating sprouting and non-sprouting angiogenesis are
required for labyrinth development. Initially, non-sprouting
angiogenesis regulated by factors such as CYR61 are required to
produce the network of chorionic plate vessels (Figure 2) [1,118].
While Hoxa13 and CYR61 homozygous mutants both exhibit
Table 1. Microarray and qRT-PCR analysis of gene transcription comparing mutant and wild-type tissue.
Affymetrix Array
Probe ID Gene
GO: Molecular Function/Biological
Process qRT-PCR Primers (59 -3 9) MUT/WT Fold Change
Whole Placenta
Microarray (FDR)
Endothelial Cell–
Specific qRT-PCR
1421201_a_at Trophinin Cell adhesion/Cell growth and organization GAACCCACGACCAGAACC – For
GCAAAATGGCCACATCTC – Rev
22.2 (0.00) 25.4
1448136_at Enpp2 Hydrolase and nucleotide diphosphatase
activity/Chemotaxis; cell motility
CCGACCTGACAATGATGAGA – For
AAATCCAAACCGGTGAGATG – Rev
22.3 (0.00) 223.1
1417217_at Magel-2 Protein binding/Regulation of transcription AACGCTTTGGTGCAGTTTCT – For
CTTAGTGTTGGCACGGTTGA – Rev
22.9 (0.00) 298.9
1449145_a_at Caveolin-1 Protein binding/Vasoconstriction; vasodilation;
EC proliferation
GGGAACAGGGCAACATCTAC – For
AACACGTCGTCGTTGAGAT – Rev
21.9 (0.00) 23.6
1423420_at Adrb1 Receptor activity/Blood pressure regulation;
vasodilation
GCTGATCTGGTCATGGGATT – For
AAGTCCAGAGCTCGCAGAAG – Rev
21.9 (0.00) 28.0
1418788_at Tie2 (Tek) Receptor activity/Regulation of angiogenesis
and cell migration; cell adhesion
TGAGGACGCTTCCACATTC – For
CAACAGCACGGTATGCAAGT – Rev
21.6 (0.00) 22.2
1429379_at Lyve1 (Xlkd1) Receptor activity; hyaluronic acid binding/Cell
adhesion
AGCCAACGAGGCCTGTAA – For
CACCTGGGGTTTGAGAAAAT – Rev
+3.6 (0.00) +4.4
1450883_a_at CD36 Receptor activity/Cell adhesion; fatty acid and
lipid metabolism and transport
GAGTTGGCGAGAAAACCAGT – For
GTCTCCGACTGGCATGAGA – Rev
22.28 (0.01) 22.9
1418084_at Neuropilin-1 Receptor activity; VEGF receptor activity/
Angiogenesis; cell migration
TGTCCTGGCCACAGAGAAG – For
CCAGTGGCAGAATGTCTTGT – Rev
21.5 (0.02) 27.4
1435382_at Necdin Transcription factor/Cell growth and migration TGGTACGTGTTGGTGAAGGA – For
AACACTCTGGCGAGGATGAC – Rev
21.8 (0.00) 27.7
1434939_at FoxF1 Transcription factor/Vasculogenesis; organ
development; ECM organization
GCAGCCATACCTTCACCAA – For
GCCATGGCATTGAAAGAGA – Rev
21.3 (0.03) 22.9
doi:10.1371/journal.pgen.1000073.t001
Table 2. Loss of HOXA13 function causes increased sinusoidal and lymphatic endothelial gene expression.
Affymetrix Array
Probe ID Gene Molecular Function/Biological Process Fold Change MUT/WT (FDR)
Whole Placenta Microarray
1429379_at Lyve-1/Xlkd1 Hyaluronate receptor: maintenance of hyaluronan status in lymphatic and sinusoidal
endothelia [101]
3.60 (0.00)
1423062_at Igfbp3 Igf Binding protein: maintenance of sinusoidal endothelial phenotype [57] 1.86 (0.00)
1450699_at Selenbp1 Selenium binding protein: maintenance of selenium status and sinusoidal endothelial
phenotype [53]
1.52 (0.00)
1427457_a_at Bmp1 Metalloprotease: cleaves prolactin to inhibit angiogenesis [54] 1.36 (0.00)
1426314_at Ednrb Endothelin receptor: promotes sinusoidal endothelial function [56] 1.19 (0.01)
doi:10.1371/journal.pgen.1000073.t002
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are more severe in CYR61 mutants, a consequence of the earlier
developmental function of CYR61 which regulates the formation
of chorionic plate vessels whose subsequent branches form the
primary vessels of the vascular labyrinth (Figure 2) [118].
Similarly, defects in labyrinth vascularization have also been
attributed to perturbations in NOTCH/DELTA signaling
[41,119–121]. In particular the loss of Notch1 function or its target
genes, Hey1 and Hey2, cause a complete loss of angiogenic
sprouting necessary to form the vascular labyrinth [41,119–121].
Similar to HOXA13, the NOTCH ligand, DLL4, appears to be
expressed in the umbilical arteries, as well as the developing
chorionic plate vessels and invading labyrinth branches [119]. In
these tissues, haploinsufficiency of DLL4 was sufficient to cause
gestational lethality, a consequence of the regression of the
chorionic plate vessels which integrate the developing umbilical
vessels to the placental labyrinth [119]. While this phenotype is
substantially different from the labyrinth defects in Hoxa13
homozygous mutants the similarities in the expression domains
of Hoxa13, Notch1, and Dll4 raise the possibility that HOXA13 and
activated Notch receptors function through common factors to
promote the angiogenic processes necessary for labyrinth devel-
opment. Factors such as NEUROPILIN-1 may be a common link
between HOXA13 and NOTCH/DELTA signaling as this
essential pro-angiogenic molecule is down-regulated in Hoxa13
(this work), Notch1, and Hey1/Hey2 mutants [41].
The formation of a functional placenta is one of the most critical
steps in human and mouse intrauterine development. In this study
we have identified a role for HOXA13 in the formation of this
vital organ. These findings suggest that HOXA13 regulates a
series of genes in the vascular endothelia that are necessary for
adhesion and vessel branching, providing a functional explanation
for the mid-gestational lethality exhibited by Hoxa13 mutant mice.
More importantly, these findings provide a novel genetic pathway
to consider when characterizing pathologies of the placenta or
placental evolutionary ontogeny.
Materials and Methods
Hoxa13-GFP Mutant Mice
All animal care and handling was done following an approved
institutional animal protocol. Mice used in this study were from
the Hoxa13-GFP line, previously described [28]. Hoxa13 mutant
embryos were derived from heterozygous intercrosses as described
[28,80]. Timed matings were used to establish embryonic
gestational age and are depicted in embryonic days (E) where
E0.5 represents the first day of vaginal plug detection. The Hoxa13
mutant allele encodes a fusion protein where the last 34 amino
acids of HOXA13, which encodes the DNA binding domain, have
been replaced with an EGFP reporter as described [28,73]. The
nuclear localization, protein turnover, and tissue-specific expres-
sion of the HOXA13-GFP protein were similar to the wild type
protein [28]. The HOXA13-GFP fusion protein produces a robust
fluorescent signal. Analyses examining endogenous HOXA13-
GFP localization are labeled as HOXA13-GFP. Because E11.5–
13.5 placentas exhibit high autofluorescence in the GFP emission
spectra it was necessary to use a GFP antibody (AB3080,
Chemicon) to visualize the co-localization of the HOXA13-GFP
with candidate target gene proteins. Characterizations of
HOXA13-GFP expression using the GFP antibody are denoted
as a-GFP in the figures. A Texas-red labeled secondary antibody
(Jackson Immunological) was used to detect the localization of the
GFP antibody.
Immunohistochemistry and In Situ Hybridization
Placentas were dissected in cold 16PBS and fixed 3 hours to
overnight in 4% paraformaldehyde/PBS at 4uC rocking. For
frozen sections, placentas were treated with a 10–30% sucrose/
PBS gradient, embedded in OCT (Tissue-Tek, Inc), and stored at
280uC. Frozen OCT-embedded placentas were sectioned at 17–
20 mm using a Leitz Kryostat 1740 and mounted on Superfrost
plus slides (Fisher). Immunohistochemistry (IHC) and in situ
hybridization (ISH) experiments were carried out as previously
described [73,80]. The Tpbp riboprobe plasmid was kindly
provided by Dr. James Cross (University of Calgary).
For whole placenta IHC, placentas were bisected with a double-
edged razor blade and fixed in 4% paraformaldehyde overnight at
4uC. After fixation the bisected placentas were dehydrated with a
4:1:1 methanol-DMSO-peroxide solution and incubated in
primary and secondary antibodies overnight followed by extensive
PBST washes. The following antibodies and dilutions were used:
PECAM-1 for section (#550274, BD Pharmingen, 1:200),
PECAM-1 for whole placenta IHC (MEC13.3, #553369 BD
Pharmingen, 1:200), GFP (AB3080, Chemicon, 1:100), Lyve1
(ab14917, Abcam, 1:200), Tie2 (#MAB1148, Chemicon, 1:200),
ENPP2 (Cosmo Bio, 1:100).
For co-localization studies, CY5- or Texas Red-labeled
secondary antibodies were used as described [73,80]. To visualize
the co-localization of PECAM-1 and LYVE1 in the vascular
endothelia, the red CY5 signal detecting the distribution of the
PECAM-1 antibody was pseudo-colored green using the Laser
Sharp 2000 software (BioRad).
Transmission Electron Microscopy (TEM)
E11.5 placentas were bisected and immediately immersed in
1.5% glutaraldehyde/1.5% paraformaldehyde with 0.05% tannic
Table 3. Loss of HOXA13 function does not affect trophoblast gene expression.
Affymetrix Array Probe ID Gene Molecular Function/Biological Process Fold Change MUT/WT (FDR)
Whole Placenta Microarray
1420601_at Gcm1 Chorionic trophoblast transcription factor [86] 21.11 (0.19)
1415808_at Tpbpa Spongiotrophoblast 21.04 (0.46)
Possible function in lysosomal protein degradation [60,62]
1425895_a_at ID1 Chorionic trophoblast transcription factor [59] 21.09 (0.20)
1422537_a_at ID2 Chorionic trophoblast transcription factor [58] 21.05 (0.45)
1420602_a_at Esx1 Labyrinth trophoblast transcription factor [62] 21.12 (0.12)
doi:10.1371/journal.pgen.1000073.t003
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in several changes of DMEM, then post-fixed in 1.0% OsO4 in
DMEM for an additional 90 minutes on ice. Fixed tissues were
rinsed in several changes of DMEM over 15 minutes, then
dehydrated in a graded ethanol series to 100%, rinsed in
propylene oxide, and finally infiltrated and embedded in Spurr’s
epoxy. Ultrathin sections were cut at 80 nm, contrasted with
uranyl acetate and lead citrate, and then examined using a Philips
410 TEM operated at 80 KV. E13.5 placentas were fixed by
perfusion using 1.5% glutaraldehyde/1.5% paraformaldehyde
with 0.05% tannic acid in DMEM, then bisected and immersed
in the same fixative for an additional 60 minutes. Post-fixation,
dehydration and embedding was identical to the E11.5 embryos
described above.
Morphological Scoring of the Labyrinth Endothelia
E13.5 placentas were sectioned at 1 mm, mounted on slides, and
counterstained with toluidine blue with basic fushin and the sections
containing the labyrinth regions were photographed. For each
placental sample, seven to ten photographs representing nearly the
complete vascular labyrinth region were taken. Within each photo,
fetal labyrinth lumens were identified, and all ECs with a visible
nucleus were counted and their morphology scored as either normal
(smooth elongated EC layer and lumen), intermediate (some cell
rounding or irregular shape), or abnormal (cell detachment, edema,
diminished cell body). Three wild type placentas (25 photos; 1510
endothelial cells), five Hoxa13 heterozygous placentas (38 photos;
1938 ECs), and five Hoxa13 homozygous mutant placentas (39
photos; 1301 ECs) were analyzed. The average percentage of each
cell morphology was calculated and plotted with their standard
deviations using Excel (Microsoft).
Quantitative Analysis of Placenta Labyrinth Thickness
and Vascular Branching
Placental labyrinth thickness was measured in 8 independent
E12.5 Hoxa13 heterozygous and homozygous mutant placentas.
The placentas were fixed, OCT embedded, and 20 mm sections
were hybridized with the Tpbp or Hoxa13 (not shown) riboprobes
to identify the labyrinth and overlying spongiotrophoblast regions.
Digital photographs were taken from two separate placental
sections that represent middle regions of each placenta, using a
Leica DML light microscope with a 106 objective and a Q-
Imaging camera. Using the NIH Image J software, labyrinth
thicknesses (in micrometers) were measured from the labyrinth-
spongiotrophoblast border to the chorionic plate at five indepen-
dent points along the placental section. For each point, three to six
independent measurements were taken. The average thickness and
standard deviation was calculated using Excel (Microsoft) and
plotted using Sigmaplot 9.0 (Systat).
Labyrinth vessel branching was quantitated using a modified
grid analysis of the labeled labyrinth vessels as described [122].
Hemisected E13.5 placentas were fixed in 4 percent paraformal-
dehyde and processed for whole mount immunohistochemistry
using the PECAM-1 antibody as described earlier. The hemisected
placentas were photographed using a Leica MZ-12.5 stereoscope
fitted with a Nikon Coolpix 990 digital camera at 46
magnification. Placenta photographs were resized to 462.5 inches
using Adobe Photoshop CS3. Three hemisected placentas were
characterized for each genotype. A 400 mm
2 (20 mm620 mm)
grid was placed at six independent locations in the labyrinth region
of the placental photographs and the PECAM-1 labeled vessels
branches present in the grid were counted. The average number of
vessel branches and their standard deviations were calculated
using Excel (Microsoft) and plotted using Sigmaplot 9.0 (Systat).
Figure 9. TIE-2 and LYVE-1 are co-expressed with HOXA13 in
the labyrinth vascular endothelia and exhibit altered expres-
sion in E13.5 homozygous mutants. (A, B) Immunohistochemical
analysis of TIE2 expression (red signal) in the placental labyrinth reveals
reduced levels in E13.5 Hoxa13 homozygous mutants compared to
heterozygous controls. (C, D) Higher magnification image of the
placental labyrinth confirms that TIE2 (red signal) is co-expressed with
HOXA13 (green nuclear signal) in the labyrinth vascular endothelia. (E,
F) Immunohistochemical analysis of LYVE-1 expression (red signal) in
the placental labyrinths reveals elevated levels of LYVE-1 in E13.5
Hoxa13 homozygous mutants compared to heterozygous controls. (G,
H) Analysis of LYVE-1 expression at higher magnification (red signal)
confirms that the PECAM-1–positive endothelial cells (green signal) co-
express LYVE-1 and that LYVE-1 expression is elevated in the labyrinth
vasculature of Hoxa13 homozygous mutants.
doi:10.1371/journal.pgen.1000073.g009
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Primary umbilical arteries entering the placenta (E13.5
embryos) were dissected free using sterilized tungsten needles.
The dissected vessels were cut into 1–3 mm sections using
sterilized microvasculature scissors (Fine Science Tools) and
embedded into 1 percent type I collagen (BD Biosciences)
containing 2.3 mg/ml sodium bicarbonate, and 26 enrichment
of EGM-2 MV base media (Lonza, Walkersville, MD) as described
Figure 10. HOXA13 binds to gene-regulatory regions in Tie2 and Foxf1 to facilitate gene expression. (A). Left panel: Chromatin
immunoprecipitation (ChIP) of heterozygous control placental chromatin using a HOXA13 antibody identified DNA sequences present in the Tie2 and
Foxf1 promoter regions and confirms that HOXA13 associates with these sequences in vivo. Right panel: Parallel assays using Hoxa13 homozygous
mutant placentas failed to enrich for the same DNA regions, suggesting that HOXA13’s DNA binding function, which is absent in the homozygous
mutant protein, is necessary for in vivo association at the Tie2 and Foxf1 loci. Input indicates positive control confirming the presence of the Tie2 and
Foxf1 DNA elements in both heterozygous and homozygous mutant chromatin samples. ChIP=+ HOXA13 antibody; No-AB=no antibody negative
control; Pre-Im=IgG control rabbit pre-immune sera; Water=no DNA PCR control (B). Sequence analysis revealed HOXA13 binding sites (red text) in
the ChIP-positive PCR amplification products for both Foxf1 and Tie2. (C) EMSA analysis of the ChIP-positive PCR amplification products confirms
HOXA13 can bind these sites in a concentration-dependent manner. A13-DBD=HOXA13 DNA binding domain peptide; Cold Comp. =the Tie2 or
Foxf1 binding sites lacking radioactive labeling. (D) The HOXA13 DNA binding domain binds the DNA sequences present in the ChIP-positive region
with high affinity exhibiting a Kd of 4864 nM for the Foxf1 region and 2761.4 nM and 2261.6 nM for the two sequences present in Tie2. Error bars
denote the standard error for the averaged millipolarization values at each HOXA13-DBD concentration. The DNA sequences of the Tie2 or Foxf1
promoter regions used in the assay are denoted by the color text. (E) Conversion of the Tie2 or Foxf1 binding sites to the sequence TGAC ablates the
affinity of the HOXA13 DNA binding domain for these gene-specific promoter sequences. Error bars denote the standard error for the averaged
millipolarization values at each HOXA13-DBD concentration. (F) In vitro assessment of the 140 bp Tie2 and 121 bp Foxf1 ChIP fragments confirms that
HOXA13 can use these minimal sites to direct gene expression, confirming their capacity to function as gene-regulatory elements. Values represent
average detected luciferase activity after normalization for transfection with a Renilla luciferase reporter6standard error.
doi:10.1371/journal.pgen.1000073.g010
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the embedding and culture of the vessel sections. After 10 minutes
of incubation at 37 degrees Celsius, the chambered slides were
filled with complete 16 EGM-2MV media supplemented with 5
percent fetal bovine serum, and the Single-QuotH growth factor/
antibiotic cocktail containing hydrocortisone, hFGF-B, VEGF,
IGF, ascorbic acid, EGF, gentamicin, and amphotericin-B as
described by the manufacturer (Lonza, Walkersville, MD). After
five days, the cultured umbilical arteries were fixed overnight in 4
percent paraformaldehyde/PBS at 4 degrees Celsius. After
fixation the cultured vessels were rinsed with 16PBS containing
1% Triton X 100, and characterized for HOXA13-GFP and
PECAM-1 expression as described [73,80].
Quantification of the Ventricular Wall Thickness
Three separate E13.5 Hoxa13 heterozygous control and
homozygous mutant embryos were fixed, paraffin-embedded,
sectioned, and stained with hematoxylin and eosin using standard
histological techniques as described [73]. The heart regions from
the sectioned embryos were photographed using a Leica DML
compound microscope and a Q-Imaging digital camera. The
cellular thickness of each ventricular wall was determined by
counting the number of hematoxylin-stained nuclei present in 6–
10 perpendicular lines drawn from outer edge of the left
ventricular wall to the trabeculae as shown in Figure 8. The
average cell number and standard deviation was calculated using
Excel (Microsoft).
Microarray and Statistical Analysis
E13.5 placentas were dissected and the isolated umbilical
vessels, embryonic labyrinth, and spongiotrophoblasts tissues were
used as the source for the embryonic placental RNA. Tissues were
dissected in RNAlater (Ambion), flash-frozen in liquid nitrogen,
and stored at 280uC. The RNA STAT-60 (CS-110, Tel-Test,
Inc.) and RNeasy Micro Kit (QIAGEN) systems were used for
RNA extraction, following the manufacturer’s protocol. RNA
quality was assessed using an Agilent Bioanalzyer at the OHSU
Affymetrix Microarray Core facility (AMC), UV spectroscopy, and
agarose gel electrophoresis. Three RNA samples of like genotype
were pooled for each microarray analysis. Twelve independent
microarray hybridizations (6 Hoxa13 homozygous mutant, 6 wild
type) were performed using the MOE430A and B microarrays
(Affymetrix). MAS 5.0 software (Affymetrix) was used by the AMC
to collect and normalize the array data. Statistical analysis of the
microarray data sets was performed by the Biostatistics and
Bioinformatics Shared Resources Core Facility at OHSU. A two-
factor analysis of variance (ANOVA) was used to determine the
false discovery rate and to compare transcript signal intensities
between wild type and homozygous mutant placental tissues.
Collection of Placenta Endothelial Cells for qRTPCR
Analysis
E13.5 placental EC were isolated by dissecting fresh placentas
as in the microarray method. Two to three placentas of the same
Hoxa13 genotype were combined. Samples were treated with 0.2%
Collagenase Type IV (#17104-019, Gibco) at 37uC for 30 min-
utes, with occasional shaking. Tissue was then transferred to a
Netwells Dish (Costar) and treated with digestion media (0.1%
Trypsin/EDTA, 0.2% Collagenase IV, in PBS) for 30 minutes at
37uC using gentle pipetting to dissociate the tissue. Magnetic beads
(Dynabeads M450, DYNAL Inc) were coated with PECAM-1
antibody (MEC 13.3, #553369 BD Pharmingen) as described by
the manufacturer. 2.5610
6 cells were dispensed into 0.7 ml micro-
tubes with the Dynabeads-PECAM1 antibody (36 more beads
than cells), and incubated for 1 hour at 4uC on rotating platform.
The bead-antibody-cell complexes were isolated using a magnet
and the remaining cell supernatant was collected as a PECAM(-)
control. The cell complexes were gently washed with 0.1% BSA/
PBS and collected for RNA extraction.
RNA was extracted from both the PECAM+ and PECAM2
cell samples using the RNA Stat-60 (CS-110-Tel-Test, Inc.) and
RNeasy Micro Kit systems (QIAGEN) and treated with DNase I
(Promega) to remove genomic DNA. RNA quality was analyzed
by UV spectroscopy and agarose gel electrophoresis. One
microgram of RNA was used for cDNA synthesis using the
Superscript First-Strand Synthesis system (Invitrogen). The SYBR-
green based system of gene expression detection was utilized to
quantify the relative levels of control and placenta-specific genes in
each cDNA sample. To distinguish amplicons generated from
genomic DNA, PCR primers were designed to span an intron-
exon boundary. Melting curves were empirically determined for
each primer set to establish precise temperature for data collection.
Reaction amplifications were performed using a 16SYBR Green
PCR Master Mix as described by the manufacturer (Applied
Biosciences). QRT-PCR reactions were performed in triplicate,
and each gene primer set was tested against a minimum of four
cDNA samples derived from independent RNA isolates. All qRT-
PCR reactions were performed using an Applied Biosystems
Model 7700 Sequence Detector. The primer sequences for the
control genes (gapdh, actin, and Pecam-1) and candidate genes are as
follows: MageL-2, For-59-GAACCCACGACCAGAACC-39, Rev-
59-CTTAGTGTTGGCACGGTTGA-39 (132 bp, Ex1); Necdin,
For-59-AACGCTTTGGTGCAGTTTCT-39, Rev-59- AACACT-
CTGGCGAGGATGAC-39 (134 bp, Ex1); Adrb1, For-59-TGG-
TACGTGTTGGTGAAGGA-39, Rev-59- AAGTCCAGAGCT-
CGCAGAAG-39 (100 bp, Ex1); Enpp2, For-59-CCGACCTGA-
CAATGATGAGA-39, Rev-59- AAATCCAAACCGGTGA-
GATG-39 (120 bp, Ex24–25); Tie2, For-59-TGAGGACGCTTC-
CACATTC-39, Rev-59- CAACAGCACGGTATGCAAGT-39
(104 bp, Ex13–14); Foxf1, For-59-GCAGCCATACCTTCAC-
CAA-39, Rev-59-GCCATGGCATTGAAAGAGA-39 (126 bp,
Ex1–2); Neuropilin-1, For-59-TGTCCTGGCCACAGAGAAG-39,
Rev-59- CCAGTGGCAGAATGTCTTGT-39 (115 bp, Ex12–
13); Caveolin-1, For-59-GGGAACAGGGCAACATCTAC-39,
Rev-59-ACCACGTCGTCGTTGAGAT-39 (136 bp, Ex1);
CD36, For-59-GAGTTGGCGAGAAAACCAGT-39, Rev-59-
GTCTCCGACTGGCATGAGA-39 (143 bp, Ex3); Lyve-1, For-
59-AGCCAACGAGGCCTGTAA-39, Rev-59-CACCTGGGGT-
TTGAGAAAAT-39 (150 bp, Ex 2–3); Pecam-1, For-59-CCAGTG-
CAGAGCGGATAAT-39, Rev-59-GCACCGAAGTACCATTT-
CAC-39 (148 bp, Ex7–8); Actin, For-59-CCTGCCATGTAT-
GTGGCTAT-39, Rev-59-CTCATAGATGGGCACGTTGT-39
(114 bp, Ex3–4); Gapdh For-59-CACTGCCACCCAGAAGAC-
TGT-39, Rev-59-GGAAGGCCATGCCAGTGA-39 (147 bp).
Chromatin Immunoprecipitation (ChIP)
Whole placentas were cut into 2 mm sections and fixed for
60 seconds in a 1% formaldehyde solution followed by treatment
with 1M glycine/PBS/protease inhibitors. The fixed tissues were
incubated 10 minutes in SDS lysis buffer (Upstate Biotech) and
homogenized using disposable plastic dowels. The released
chromatin was sheared at 4uC using a Biorupter sonicator
(CosmoBio, Japan). Proper sonication was confirmed by agarose
gel electrophoresis. A ChIP assay kit (Upstate Biotech) was used to
isolate HOXA13-DNA fragments from sheared placental chro-
matin. Prior to ChIP, the presence of the HOXA13 protein in the
sheared chromatin was confirmed by western-immunoblot using
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produced by the HOXA13-ChIP assay was examined for the Foxf1
and Tie2 promoter sequences containing the previously described
HOXA13 binding sites [71] using PCR and 30 cycles of 94
degrees Celsius for 30 seconds, 54 degrees Celsius for 30 seconds,
and 72 degrees Celsius for 30 seconds. Primers flanking the
potential HOXA13 binding sites were selected using the genomic
sequences listed for Foxf1 (Ensembl:MUSG00000042812) and Tie2
(Ensembl:MUSG00000006386). The PCR primers were: Foxf1#1
(22368 to 22231, 138 bp), For-59-TGAGGTACAGCCCAGAG-
TCC-39, Rev-59-CACACCCCCAAGTTTTCTTC-39; Foxf1#2
(21284 to 21163, 122 bp), For-59-CGCGGGCTTCTCTACT-
CTTA-39, Rev-59-CCTTTTACAAGCGCAGGTTC-39; Tie2#1
(22413 to 22273, 141 bp), For-59-GGGAAGGGGAGTGGA-
TAACA-39,R e v - 5 9-CTAATCCCAGCCCTGCTGTA-39; Tie2#2
(2859 to 2702, 158 bp), For-59-CTTCCTGTGCCAAG-
TTCTCC-39,R e v - 5 9- GACCAGATTCCACAGCCATT-39.E a c h
ChIP assay was performed at least two times using unique placenta
samples in order to confirm the ChIP results.
Electrophoretic Mobility Shift Assays and Luciferase
Assays
The HOXA13 DNA-binding domain peptide was purified and
gel shifts performed as previously described [72]. The Foxf1 and
Tie2 primers described in the ChIP assay were used to amplify the
genomic regions for the EMSA assay. The amplified PCR
products were isolated using the QIAquick Gel Extraction Kit
(Qiagen), quantified by UV spectroscopy, and sequenced to
confirm the correct gene promoter sequence. PCR amplicons were
radiolabeled using c-
32P dATP (3000 Ci/mmol; 1Ci-37 GBq) and
T4 polynucleotide kinase as described by the manufacturer
(Promega). EMSA assays were performed using the Gel Shift
Binding System following manufacturer’s protocol (Promega).
The 121 bp Foxf1 and 140 bp Tie2 DNA elements identified by
ChIP to be bound by HOXA13 in the labyrinth vascular
endothelia were evaluated in vitro for their capacity to facilitate
gene expression in the presence of HOXA13. Based on the small
size of these ChIP-positive DNA sequences as well as our previous
characterization of HOXA13’s relatively low in vitro transcriptional
activity, a promoter- and enhancer-less luciferase reporter plasmid,
pGL3-Basic (Promega), was selected for this analysis [65,66]. The
pGL3-Basic vector has been previously shown to measure minimal
promoter activity with high reproducibility [71,72,74–77,124].
Luciferase assays and cell culture were performed as previously
described [71,72]. The NG108-15 cell line (ATCC#HB-12317)
was selected for the luciferase assay based on the absence of
endogenous HOXA13 expression [124]. Transfections were
performed in 12 well plates (Costar) using 2 mg of the Tie2 or
Foxf1 luciferase vectors, 0.25 mg pRL-CMV Renilla, and 0.5 mg
pCAGGS-Hoxa13 or empty pCAGGS control plasmid per well as
described [71]. Cell lysates were processed to detect luciferase
activity using the Dual-Glo Luciferase Assay System (Promega) in
OptiPlate-96F black plates (Packard) as described (Promega) [72].
Luciferase activity was detected using a Packard Fusion Micro-
plate Analyzer (Perkin Elmer), wells were read 3 times for 1 sec
each and averaged. Three replicates of each transfection were
performed and each transfection assay was repeated 3 times.
Results were normalized for Renilla expression and averaged. The
averaged data and standard errors were plotted using SigmaPlot
9.0 (Systat).
Fluorescence Anisotropy
Quantification of HOXA13 affinity for the binding sites present
in Foxf1 and Tie2 was determined by fluorescence polarization (FP)
anisotropy as described [71]. Fluorescein-labeled self-annealing
hairpin oligonucleotides specific for the binding sites in the ChIP-
positive regions of Tie2 and Foxf1 were synthesized by Integrated
DNA Technologies (Coralville, IA): Tie2#1: 59-ctgtaattaaa-
taccccccgtatttaattacag-39; Tie2#2: 59-catttaataaaaaccccccgtttttat-
taaatg-39; Foxf1:5 9-cttattattaaaggccccccctttaataataag-39; TGAC
control: 59-tgactgactgactgccccccagtcagtcagtca-39. 1 nM of the
annealed fluorescein-labeled oligonucleotides was incubated with
0–200 nM HOXA13-DBD peptide at 15 degrees Celsius and the
FP values were measured using the Beacon 2000 Fluorescence
Polarization System (Invitrogen). The detected millipolarization
values (mP) were plotted using a non-linear least squares fit
iteration as described [71]. Each data point represents an average
(6standard error) of 3 or more independently derived mP values
for each concentration of HOXA13-DBD peptide.
Supporting Information
Figure S1. Developmental analysis of labyrinth formation and
pro-vascular gene expression. (A, B) PECAM-1 immunostaining
revealed no difference in labyrinth vascular bed initiation between
Hoxa13 control (+/2) and homozygous mutants at E10.5. (C–F)
Hoxa13 homozygous mutants exhibit a decrease in primary
vascular branching as early as E11.5 compared to wild-type
controls. (E) and (F) represent higher magnification images of the
PECAM-1 stained vessels depicted in (C) and (D), respectively. (G–
J) TIE2 expression is reduced in the labyrinth region of Hoxa13
homozygous mutants compared to heterozygous controls at both
the initial stages of labyrinth formation at E10.5 and during
primary vessel branching at E12.5. (K–N) Hoxa13 homozygous
mutant placental labyrinths exhibit a consistent increase in
LYVE1 immunostaining compared to controls at E11.5 and
E12.5.
Found at: doi:10.1371/journal.pgen.1000073.s001 (1.50 MB TIF)
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